Subsequent Disclosure Clause Samples

Subsequent Disclosure. Notwithstanding the foregoing, to the extent information regarding this Agreement or the Product has already been publicly disclosed, either Party (or its Affiliates) may subsequently disclose the same information to the public without the consent of the other Party.

Subsequent Disclosure. The Contractor shall not release, divulge, publish, transfer, sell, disclose, or otherwise make the Confidential Information or Sensitive Data known to any other entity or person without the express prior written consent of the Authority’s Public Disclosure Office, or as required by law. If responding to public record disclosure requests under Chapter 42.56 RCW, the Contractor agrees to notify and discuss with the Authority’s Public Disclosure Officer requests for all information that are part of this Contract, prior to disclosing the information. The Authority upon request shall provide the Contractor with the name and contact information for the Authority Public Disclosure Officer. The Contractor further agrees to provide the Authority with a minimum of two calendar weeks to initiate legal action to secure a protective order under RCW 42.56.540.

Subsequent Disclosure. If the Codexis Alliance Manager requests further information regarding Arising GSK Enzyme Technology and/or Arising GSK Process Technology, Codexis shall, within [***] days after receipt of the initial disclosure of such Arising GSK Enzyme Technology and/or such Arising GSK Process Technology by GSK pursuant to Section 2.2.10(a) request the disclosure of such further information Controlled by GSK.

Subsequent Disclosure. For the avoidance of doubt and notwithstanding any other provision of this Section 6.5 to the contrary, following the Effective Date, the confidentiality obligations under this Agreement shall continue to apply to any and all Confidential Information concerning or belonging to each Party or its Affiliates that is shared or disclosed with the other Party or its Affiliates, whether or not such Confidential Information is shared pursuant to this Agreement, any Ancillary Agreement or otherwise.

Subsequent Disclosure. If the GSK Alliance Manager requests further information regarding Codexis Core Technology Improvements, Arising Codexis Enzyme Technology and/or Arising Codexis Process Technology by or on behalf of Codexis, or any Affiliate of Codexis, and [***] corresponding Licensed Additional IP during the TT Term and, if GSK exercises the Option, during the Improvements TT Term, and corresponding Licensed Additional Codexis IP disclosed to GSK in accordance with Section 2.2.9(a), GSK shall, within [***] days after receipt of the initial disclosure of Codexis Core Technology Improvements by Codexis pursuant to Section 2.2.9(a) request the disclosure of such further information Controlled by Codexis, and with respect to Section 2.2.9(a), in sufficient detail as reasonably necessary for GSK to make a decision as to whether to exercise its rights pursuant to Section 3.5.2 to obtain a license to such Codexis Core Technology Improvements and corresponding Licensed Additional Codexis IP. All information, documents and other materials disclosed by Codexis to GSK pursuant to this Section 2.2.9 shall constitute the Confidential Information of Codexis.

Subsequent Disclosure. After such initial press release, except as otherwise provided in this Section 16.11(ii), neither Licensor nor Licensee (the “Releasing Party”) may issue a press release or public announcement relating to this Agreement without the prior written approval of the other Party (the “Non-Releasing Party”), which approval shall not be unreasonably withheld, conditioned or delayed, except that the Releasing Party may: - 62 - of - 75 - (a) issue such press release or public announcement if the contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by the Releasing Party; (b) issue such a press release or public announcement if required by applicable Laws and Regulations, including by the rules or regulations of the Taiwan OTC, the French securities authorities or similar regulatory agency in a country other than Taiwan or France; and (c) issue such a press release or public announcement regarding: (1) the commencement, completion or “top-line” results of preclinical and clinical studies of the Licensed Product; (2) the completion of subject enrollments for clinical studies of the Licensed Product; (3) the filing or receipt of Regulatory Approval with respect to the Licensed Product; and (4) such Party’s Commercialization activities with respect to the Licensed Product hereunder, including the development of sales, marketing and medical infrastructure and management changes to support Development and Commercialization activities; (5) receipt of milestone payments; in each case under clause (a), (b) or (c) after first notifying the Non-Releasing Party of such planned press release or public announcement at least five (5) Business Days in advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements made pursuant to the foregoing clause (ii), with as much advance notice as possible under the circumstances if it is not possible to provide notice at least five (5) Business Days in advance) for the sole purpose of allowing the Non-Releasing Party to review the proposed press release or public announcement. The Releasing Party shall modify any such press release or public announcement as reasonably requested by the Non-Releasing Party to remove any Confidential Information of the Non-Releasing Party and shall include in such press release or public announcement made pursuant to the foregoing clause (ii) only such informatio...

Subsequent Disclosure. Subject to Clause 8.4, if at any time before Closing, any of the Warrantors comes to know of any fact or event which, save for any matter already qualified herein by specific reference to any Schedule hereto: (a) is in any way inconsistent with any of the representations and warranties given by any of the Warrantors resulting in a Material Adverse Event, (b) suggests that any fact warranted by any of the Warrantors may not be as warranted or may be misleading resulting in a Material Adverse Event, and/or (c) would be material to any decision made by KongZhong or KongZhong Nominee of whether or not to consummate the share purchase transactions under this Agreement and the Xinrui Share Purchase Agreement, (d) the Warrantor shall give immediate written notice thereof to KongZhong, or as the case may be, KongZhong Nominee and the other Parties and rectify the matters to the satisfaction of KongZhong within five (5) Business Days from the date the written notice is delivered to KongZhng or KongZhong Nominee, and in the event the Warrantor fails to rectify the matters to the satisfaction of KongZhong within the 5-day period, KongZhong, or as the case may be, KongZhong Nominee, may terminate this Agreement without any penalty whatsoever, by delivering written notice of such termination, within fourteen (14) Business Days from the expiration of the 5-day period.

Subsequent Disclosure. If at any time before Closing, any of the Warrantors comes to know of any fact or event which, save for any matter already qualified herein by specific reference to any Schedule hereto: (a) is in any way inconsistent with any of the representations and warranties given by any of the Warrantors resulting in a Material Adverse Event, and/or (b) suggests that any fact warranted by any of the Warrantors may not be as warranted or may be misleading resulting in a Material Adverse Event, and/or (c) would be material to any decision made by a prudent strategic investor in similar situations as to whether or not to enter into this Agreement and/or consummate the transactions contemplated herein the Warrantor shall give immediate written notice thereof to TWM and the other Parties and rectify the matters to the satisfaction of TWM within five (5) Business Days from the date the written notice is delivered to TWM, and in the event the Warrantor fails to rectify the matters to the satisfaction of TWM within the 5-day period, TWM may terminate this Agreement without any penalty whatsoever, by delivering written notice of such termination, within fourteen (14) Business Days from the expiration of the 5-day period.

Subsequent Disclosure. No Indemnified Party shall be entitled to any indemnity for Indemnifiable Damages to the extent that the existence of such Indemnifiable Damages, the breach of covenant or warranty or the falsity of the representation upon which such Indemnifiable Damages would be based is disclosed in the SoftDent Disclosure Schedule (in the case of a SoftDent Indemnified Party) or the PracticeWorks Disclosure Schedule (in the case of a PracticeWorks Indemnified Party); provided that any such misrepresentation or breach of warranty or covenant so disclosed after execution and delivery of this Agreement and prior to Closing shall not affect the right of InfoCure, PracticeWorks, or Dentsply, as the case may be, to elect not to close the transactions contemplated by this Agreement to the extent provided in Section 6 or Section 7, as the case may be.